Evidence map›Paper›PMID 41036340›Full record

ArticleOpen veterinary journal2025

Investigation of cisplatin-induced acute kidney injury using LC-HRMS and network pharmacology approaches in mixed

Putri Reno Intan, Sukmayati Alegantina, Ani Isnawati, Lucie Widowati, Dian Sundari, Frans Dany, Agus Saputra, Sela Septima Mariya, Lina Noviyanti Sutardi, Agus Setiyono and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Putri Reno IntanAnimal Biomedical Study Program, IPB Postgraduate School, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia.
Sukmayati AlegantinaResearch Center for Pharmaceutical Ingredients and Traditional Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Ani IsnawatiResearch Center for Pharmaceutical Ingredients and Traditional Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Lucie WidowatiResearch Center for Pharmaceutical Ingredients and Traditional Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Dian SundariResearch Center for Public Health and Nutrition, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Frans DanyCenter for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Agus SaputraDepartment of Anatomy, Physiology, Pharmacology, and Biochemistry, Faculty of Medicine and Veterinary Medicine, Universitas Nusa Cendana, Kupang NTT, Indonesia.
Sela Septima MariyaCenter for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, Indonesia.
Lina Noviyanti SutardiDivision of Pharmacy, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia.
Agus SetiyonoDivision of Pathology, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia.
Ekowati HandharyaniDivision of Pathology, School of Veterinary Medicine and Biomedical Sciences, IPB University, Bogor, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cisplatin-induced acute kidney injury (AKI) is a serious complication of cancer therapy. Natural compounds, such as those found in Aim: This study investigated the therapeutic mechanisms of combined Methods: An ethanolic extract was prepared and analyzed using UHPLC-Q-Orbitrap HRMS to identify active compounds. The antioxidant capacity was assessed using the Diphenyl-2-picryl-hydrazyl assay. Network pharmacology was used to predict compound-target interactions and identify key proteins involved in AKI pathways. Results: UHPLC-Q-Orbitrap HRMS analysis identified 40 bioactive compounds, among which 22 met the OB >30% threshold. Network analysis revealed 14 overlapping protein targets associated with AKI from 485 compound-related targets and 198 disease-related targets. Conclusion: This study demonstrated that key phytochemicals in

Indexed as

Acute Kidney InjuryCisplatinCurcumaPlant ExtractsAnimalsAntineoplastic AgentsAntioxidantsChromatography, High Pressure LiquidMaleMass SpectrometryNetwork PharmacologyAntineoplastic AgentsAntioxidantsCisplatinPlant ExtractsCurcuma longaKidney damageNetwork pharmacologyUHPLC-Q-Orbitrap HRMSZedoaria

Identifiers

PMID41036340
PMCPMC12483403

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.